| 商品名称 | Pazenir |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Breast Neoplasms |
| 通用名/非专利名称 | paclitaxel |
| 活性成分 | paclitaxel |
| 产品号 | EMEA/H/C/004441 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L01CD01 |
| 是否额外监管 | Nei |
| 是否仿制药或hybrid药物 | Já |
| 是否生物类似药 | Nei |
| 是否附条件批准 | Nei |
| 是否特殊情形 | Nei |
| 是否加速审评 | Nei |
| 是否罕用药 | Nei |
| 上市许可日期 | 2019/05/06 |
| 上市许可开发者/申请人/持有人 | ratiopharm GmbH |
| 人用药物治疗学分组 | Antineoplastic agents |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2019/02/28 |
| 欧盟委员会决定日期 | 2025/06/19 |
| 修订号 | 10 |
| 治疗适应症 | Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2019/05/23 |
| 最后更新日期 | 2025/06/19 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/pazenir-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/pazenir |